Bayer Announces 2013 Recipients of Bayer Hemophilia Awards Program

Dr. Carl Blobel, M.D., Ph.D., is among Recipients to Receive Prestigious Award

Bayer Healthcare Pharmaceuticals—July 9, 2013

Bayer HealthCare has announced the 2013 recipients of the Bayer Hemophilia Awards Program (BHAP). This year, the company awarded more than $2 million in funding to 16 recipients in nine countries, including six in the U.S. BHAP is the largest program of its kind in hemophilia, funding innovative research and educational initiatives around the world.

Since its founding in 2002, BHAP has awarded more than 220 grants, totaling more than $26 million, to researchers and caregivers from 30 countries around the world. BHAP support has contributed to more than 400 publications, poster presentations and other scientific communications by awardees.

"We’re thrilled to honor this year’s award recipients, whose research will help provide greater understanding of many aspects of hemophilia in the future," said Prasad Mathew, Vice President, Global Medical Affairs Hematology, Bayer HealthCare. “BHAP is a reflection of Bayer’s ongoing commitment to research that advances scientific understanding of hemophilia and helps improve patient care.”

Research funding will cover many different aspects of hemophilia such as overcoming immunological barriers to AAV gene therapy, and stem cell transplantation therapy for hemophilia, among others. This year’s U.S. winners include:

  • Carl Blobel, Hospital for Special Surgery, Role of the iRhom2/TACE/TNFa signaling axis in hemophilic arthropathy

Read the press release at pharman.bayer.com.

^ Back to Top
Request an Appointment